Neurometrix Inc (NURO) 1.75 $NURO
NeuroMetrix Reports Second Quarter 2014 Financial Results and Business Highlights
Business Wire - Thu Jul 24, 6:00AM CDT
--FDA regulatory clearance for over-the-counter wearable technology to treat chronic pain
NeuroMetrix Marks 10th Year Anniversary of Listing on NASDAQ
Business Wire - Tue Jul 22, 6:00AM CDT
NeuroMetrix, Inc. (NASDAQ: NURO) reported today that it had reached the 10th anniversary of its initial listing on NASDAQ.
NeuroMetrix, Inc. Announces Date for 2014 Second Quarter Financial Results Conference Call
Business Wire - Thu Jul 17, 2:32PM CDT
NeuroMetrix, Inc. (the "Company"
(Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, today said it plans to issue its 2014 second quarter financial results before the opening of the market on July 24, 2014. The Company will host a conference call at 8:00 a.m., Eastern Daylight Time on July 24, 2014 to discuss its financial results as well as business developments affecting the Company.
Healthcare Companies Announce Upcoming Earnings Schedules, and Receive FDA Approvals and Clearances - Analyst Notes on WellPoint, Anacor, NeuroMetrix, Ophthotech and Emergent BioSolutions
PR Newswire - Fri Jul 11, 5:00AM CDT
Today, Analysts Review released its analysts' notes regarding WellPoint Inc. (NYSE: WLP), Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC), NeuroMetrix Inc. (NASDAQ: NURO), Ophthotech Corporation (NASDAQ: OPHT) and Emergent BioSolutions, Inc. (NYSE: EBS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4686-100free.
NeuroMetrix's OTC Pain Management Device Gets FDA Nod, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 1:50PM CDT
Following the news, NeuroMetrix's (NURO) share price surged 19% to eventually close at $2.25 yesterday.
Why NeuroMetrix (NURO) Stock Is Soaring Today
at The Street - Tue Jul 08, 9:21AM CDT
NeuroMetrix (NURO) soared Tuesday after the FDA cleared the medical device company's wearable technology for over-the-counter use in treating chronic pain.
FDA Clears NeuroMetrix Wearable Technology for Over-the-Counter Use in Treatment of Chronic Pain
Business Wire - Tue Jul 08, 6:00AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its wearable technology for treatment of chronic pain received 510(k) clearance (K140333) from the U.S. Food and Drug Administration (FDA) for over-the-counter use.
NICE Guidelines to Boost Boston Scientific's Rhythm Management - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 27, 2:00PM CDT
The new guidance released by NICE on use of cardiac technologies for arrhythmias and heart failure is expected to boost Boston Scientific Corporation's (BSX) Rhythm Management business in Europe.
Haemonetics Suffers on Dismal Q4, Poor FY15 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 27, 1:55PM CDT
On Jun 27, 2014, we issued an updated research report on Haemonetics Corporation (HAE).
Omeros Corporation (OMER) Gains: Stock Up 8.92% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 26, 7:44AM CDT
Omeros Corporation (OMER) was a big mover last session, as the company saw its shares rise 9% on the day.
Quality Systems Teams Up With 3M Health Information Systems - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 25, 12:50PM CDT
Quality Systems (QSII) continues to report a fall in earnings and revenues but we are still optimistic about the company given the continued strength in its NextGen subsidiary as well as the expected benefit from its Mirth acquisition.
Cerner Enters New Agreement with North Carolina's Mission Health - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 25, 12:40PM CDT
Under the new agreement, signed on Mar 28, Cerner Corporation (CERN) will help Mission Health control IT costs, align strategies, and improve the quality of care.
LeMaitre Vascular (LMAT) Soars: Stock Adds 10.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 25, 7:51AM CDT
LeMaitre Vascular, Inc. (LMAT) was a big mover last session, as its shares rose nearly 11% on the day.
Nasdaq stocks posting largest volume increases
AP - Tue Jun 24, 5:05PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
NeuroMetrix Announces $8 Million Preferred Stock Placement
Business Wire - Tue Jun 24, 4:31PM CDT
NeuroMetrix, Inc. (Nasdaq:NURO) (the "Company" or "NURO" , an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, today announced that it entered into a definitive securities purchase agreement with a single institutional investor providing for the issuance of $8,000,000 of shares of common stock and Series A-3 and Series A-4 convertible preferred stock (for a combined total of 3,921,569 shares of common stock, either outright or issuable upon conversion of the preferred stock) and five year warrants to purchase up to 3,921,569 shares of common stock at an exercise price of $2.04 per share. Subject to certain ownership limitations, the Series A-3 and Series A-4 convertible preferred stock is convertible at any time into shares of common stock at an initial conversion price of $2.04 per share (which represents a price 8.5% above the closing price of the common stock on the previous trading day). The preferred stock is not entitled to dividends and will not have any preferences over the Company's common stock, including liquidation rights.
Why NeuroMetrix (NURO) Stock Is Surging Today
at The Street - Tue Jun 24, 11:20AM CDT
NeuroMetrix (NURO) surged Tuesday after the medical technology developer reported Japanese regulatory approval for NC-stat DPNCheck.
Strength Seen in TG Therapeutics, Inc. (TGTX) as Stock Rallies 12.94% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jun 24, 7:44AM CDT
TG Therapeutics, Inc. (TGTX) was a big mover last session, as the company saw its shares surge nearly 13% on the day.
NeuroMetrix Reports Japan Regulatory Approval for NC-stat DPNCheck
Business Wire - Tue Jun 24, 6:00AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, today reported the receipt of marketing certification from Technischer Uberwachungs-Verein SUD Japan Ltd. (TUV SUD Japan) for NC-stat DPNCheck as a Class II Designated Controlled Medical Device as defined in the technical standards of the Japan Ministry of Health, Labor, and Welfare.
Greatbatch Touches a New 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 4:00PM CDT
Impressive first-quarter 2014 results indicating double-digit bottom-line growth, strategic restructuring efforts along with accretive investments in sales and marketing led to the growth trajectory of Greatbatch, Inc. (GB).
CareFusion Reaches a New 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 3:10PM CDT
Shares of CareFusion Corporation (CFN) have been on the rise since it reported strong third-quarter fiscal 2014 (ended Mar 31, 2014) results on May 5.
NeuroMetrix Reports Second Quarter 2014 Financial Results and Business Highlights
Business Wire - Thu Jul 24, 6:00AM CDT
--FDA regulatory clearance for over-the-counter wearable technology to treat chronic pain
NeuroMetrix Marks 10th Year Anniversary of Listing on NASDAQ
Business Wire - Tue Jul 22, 6:00AM CDT
NeuroMetrix, Inc. (NASDAQ: NURO) reported today that it had reached the 10th anniversary of its initial listing on NASDAQ.
NeuroMetrix, Inc. Announces Date for 2014 Second Quarter Financial Results Conference Call
Business Wire - Thu Jul 17, 2:32PM CDT
NeuroMetrix, Inc. (the "Company"
(Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, today said it plans to issue its 2014 second quarter financial results before the opening of the market on July 24, 2014. The Company will host a conference call at 8:00 a.m., Eastern Daylight Time on July 24, 2014 to discuss its financial results as well as business developments affecting the Company. Healthcare Companies Announce Upcoming Earnings Schedules, and Receive FDA Approvals and Clearances - Analyst Notes on WellPoint, Anacor, NeuroMetrix, Ophthotech and Emergent BioSolutions
PR Newswire - Fri Jul 11, 5:00AM CDT
Today, Analysts Review released its analysts' notes regarding WellPoint Inc. (NYSE: WLP), Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC), NeuroMetrix Inc. (NASDAQ: NURO), Ophthotech Corporation (NASDAQ: OPHT) and Emergent BioSolutions, Inc. (NYSE: EBS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4686-100free.
NeuroMetrix's OTC Pain Management Device Gets FDA Nod, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 1:50PM CDT
Following the news, NeuroMetrix's (NURO) share price surged 19% to eventually close at $2.25 yesterday.
Why NeuroMetrix (NURO) Stock Is Soaring Today
at The Street - Tue Jul 08, 9:21AM CDT
NeuroMetrix (NURO) soared Tuesday after the FDA cleared the medical device company's wearable technology for over-the-counter use in treating chronic pain.
FDA Clears NeuroMetrix Wearable Technology for Over-the-Counter Use in Treatment of Chronic Pain
Business Wire - Tue Jul 08, 6:00AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its wearable technology for treatment of chronic pain received 510(k) clearance (K140333) from the U.S. Food and Drug Administration (FDA) for over-the-counter use.
NICE Guidelines to Boost Boston Scientific's Rhythm Management - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 27, 2:00PM CDT
The new guidance released by NICE on use of cardiac technologies for arrhythmias and heart failure is expected to boost Boston Scientific Corporation's (BSX) Rhythm Management business in Europe.
Haemonetics Suffers on Dismal Q4, Poor FY15 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 27, 1:55PM CDT
On Jun 27, 2014, we issued an updated research report on Haemonetics Corporation (HAE).
Omeros Corporation (OMER) Gains: Stock Up 8.92% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 26, 7:44AM CDT
Omeros Corporation (OMER) was a big mover last session, as the company saw its shares rise 9% on the day.
Quality Systems Teams Up With 3M Health Information Systems - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 25, 12:50PM CDT
Quality Systems (QSII) continues to report a fall in earnings and revenues but we are still optimistic about the company given the continued strength in its NextGen subsidiary as well as the expected benefit from its Mirth acquisition.
Cerner Enters New Agreement with North Carolina's Mission Health - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 25, 12:40PM CDT
Under the new agreement, signed on Mar 28, Cerner Corporation (CERN) will help Mission Health control IT costs, align strategies, and improve the quality of care.
LeMaitre Vascular (LMAT) Soars: Stock Adds 10.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 25, 7:51AM CDT
LeMaitre Vascular, Inc. (LMAT) was a big mover last session, as its shares rose nearly 11% on the day.
Nasdaq stocks posting largest volume increases
AP - Tue Jun 24, 5:05PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
NeuroMetrix Announces $8 Million Preferred Stock Placement
Business Wire - Tue Jun 24, 4:31PM CDT
NeuroMetrix, Inc. (Nasdaq:NURO) (the "Company" or "NURO"
, an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, today announced that it entered into a definitive securities purchase agreement with a single institutional investor providing for the issuance of $8,000,000 of shares of common stock and Series A-3 and Series A-4 convertible preferred stock (for a combined total of 3,921,569 shares of common stock, either outright or issuable upon conversion of the preferred stock) and five year warrants to purchase up to 3,921,569 shares of common stock at an exercise price of $2.04 per share. Subject to certain ownership limitations, the Series A-3 and Series A-4 convertible preferred stock is convertible at any time into shares of common stock at an initial conversion price of $2.04 per share (which represents a price 8.5% above the closing price of the common stock on the previous trading day). The preferred stock is not entitled to dividends and will not have any preferences over the Company's common stock, including liquidation rights. Why NeuroMetrix (NURO) Stock Is Surging Today
at The Street - Tue Jun 24, 11:20AM CDT
NeuroMetrix (NURO) surged Tuesday after the medical technology developer reported Japanese regulatory approval for NC-stat DPNCheck.
Strength Seen in TG Therapeutics, Inc. (TGTX) as Stock Rallies 12.94% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jun 24, 7:44AM CDT
TG Therapeutics, Inc. (TGTX) was a big mover last session, as the company saw its shares surge nearly 13% on the day.
NeuroMetrix Reports Japan Regulatory Approval for NC-stat DPNCheck
Business Wire - Tue Jun 24, 6:00AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, today reported the receipt of marketing certification from Technischer Uberwachungs-Verein SUD Japan Ltd. (TUV SUD Japan) for NC-stat DPNCheck as a Class II Designated Controlled Medical Device as defined in the technical standards of the Japan Ministry of Health, Labor, and Welfare.
Greatbatch Touches a New 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 4:00PM CDT
Impressive first-quarter 2014 results indicating double-digit bottom-line growth, strategic restructuring efforts along with accretive investments in sales and marketing led to the growth trajectory of Greatbatch, Inc. (GB).
CareFusion Reaches a New 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 3:10PM CDT
Shares of CareFusion Corporation (CFN) have been on the rise since it reported strong third-quarter fiscal 2014 (ended Mar 31, 2014) results on May 5.
